GBR 12783 dihydrochloride
A very potent and selective inhibitor of dopamine uptake (IC50 for inhibition of [3H]-dopamine uptake in rat striatal synaptosomes is 1.8 nM).
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|DMSO||24.27||50mM with gentle warming|
|ethanol||2.43||5mM with gentle warming|
|water||4.86||10mM with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 485.5. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.06 mL||10.3 mL||20.6 mL|
|5 mM||0.41 mL||2.06 mL||4.12 mL|
|10 mM||0.21 mL||1.03 mL||2.06 mL|
|50 mM||0.04 mL||0.21 mL||0.41 mL|
References are publications that support the products' biological activity.
Bonnet and Constentin (1986) GBR 12783, a potent and selective inhibitor of dopamine uptake: biochemical studies in vivo and ex vivo. Eur.J.Pharmacol. 121 199 PMID: 3754516
Do-Rego et al (1999) Evidence for the sequential formation of two complexes between an uptake inhibitor, GBR 12783 [1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl-2-propenyl)piperazine], and the neuronal transporter of dopamine. J.Neurochem. 72 396 PMID: 9886093
Giros et al (1992) Cloning, pharmacological characterization and chromosome assignment of the human dopamine transporter. Mol.Pharmacol. 42 383 PMID: 1406597
Vaugeois et al (1992) In vivo labelling of the neuronal dopamine uptake complex in the mouse striatum by [3H]GBR 12783. Eur.J.Pharmacol. 210 77 PMID: 1350989
If you know of a relevant reference for GBR 12783 dihydrochloride, please let us know.
View Related Products by Product Action
Keywords: GBR 12783 dihydrochloride, supplier, Potent, selective, dopamine, reuptake, inhibitors, inhibits, DAT, Dopamine, Transporters, Monoamine, Neurotransmitter, GBR12783, dihydrochloride, Dopamine, Transporters, Dopamine, Transporters, Tocris Bioscience
2 Citations for GBR 12783 dihydrochloride
Citations are publications that use Tocris products. Selected citations for GBR 12783 dihydrochloride include:
Ferreira et al (2012) Presynaptic CB(1) cannabinoid receptors control frontocortical serotonin and glutamate release--species differences. J Pharmacol Exp Ther 61 219 PMID: 22609378
Ferraro et al (2012) A novel mechanism of cocaine to enhance dopamine d2-like receptor mediated neurochemical and behavioral effects. An in vivo and in vitro study. Neuropsychopharmacology 37 1856 PMID: 22453136
Do you know of a great paper that uses GBR 12783 dihydrochloride from Tocris? If so please let us know.
Reviews for GBR 12783 dihydrochloride
There are currently no reviews for this product. Be the first to review GBR 12783 dihydrochloride and earn rewards!
Have you used GBR 12783 dihydrochloride?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.